05 May [MCE]: New Bioactive Molecules for May 2022
MedChemExpress (MCE) offers a wide range of high quality research chemicals and biochemicals including novel bioactive compounds, dye reagents, peptides and natural compounds for laboratory and scientific use.
• Over 30,000 bioactive molecules in stock
• Target 500+ key proteins in 20+ signaling pathways
• Quality reports (LC/MS, NMR and HPLC) for each product
• Release more than 500 newest biochemicals per month
• Data sheet with detailed biological information
• High purity & competitive prices
CAS No.: 1592908-75-2
MSN-50
Research Area: Bax/Bak Inhibitor/Acute and Chronic Degenerative Diseases
• Potent Bax/Bak oligomerization inhibitor that prevents mitochondrial outer membrane permeabilization (MOMP).
• Prevents genotoxic cell death and promotes neuroprotection.
Solubility: DMSO : 200 mg/mL (290.44 mM; Need ultrasonic)
CAS No.: 2377858-38-1
SCR130
Research Area: NHEJ Inhibitor/Leukaemia
• SCR7-based DNA nonhomologous end-joining (NHEJ) inhibitor and inhibits the end-joining of DNA in a Ligase IV-dependent manner.
• Induces cell apoptosis and has anticancer activity.
Solubility: DMSO : 100 mg/mL (239.06 mM; Need ultrasonic and warming)
CAS No.: 1582289-91-5
ACT001
Research Area: PAI-1 Inhibitor/Glioblastoma
• Potent, orally active PAI-1 inhibitor with anti-glioblastoma and immunomodulatory effects.
• Can cross the blood-brain barrier and inhibits the phosphorylation of STAT3 and PD-L1 expression by directly binding to STAT3.
• Exerts synergistic effects in combination with Cisplatin by inhibiting PI3K/AKT pathway in glioma.
Solubility:
DMSO : 100 mg/mL (244.22 mM; ultrasonic and warming to 60°C)
H2O : 100 mg/mL (244.22 mM; Need ultrasonic)
SAH-SOS1A TFA
Research Area: SOS1/KRAS Interaction Inhibitor/KRAS-Driven Cancer
• Peptide-based SOS1/KRAS protein interaction inhibitor and binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC50=106-175 nM).
• Directly inhibits nucleotide association to KRAS, impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS.
Solubility: H2O : 33.33 mg/mL (14.48 mM; Need ultrasonic)
CAS No.: 101303-98-4
Zacopride Hydrochloride
Research Area: 5-HT3 Receptor Antagonist/Schizophrenia
• Highly potent 5-HT3 receptor antagonist with Kis of 0.38 nM and 373 nM for 5-HT3 receptor and 5-HT4 receptor, respectively.
• Moderate IK1 channel agonist, exerts significant antiarrhythmic and cardiac protective effects.
Solubility: DMSO : 100 mg/mL (288.81 mM; Need ultrasonic)
Cytotoxicity LDH Assay Kit
The loss of cell membrane integrity due to cell death or membrane damage results in release of certain soluble, cytosolic enzymes. Therefore, acute cytotoxicity can be measured by measuring activity of these enzymes released into the culture supernatant. Lactate dehydragenase (LDH) is a stable enzyme, present in all cell types, and rapidly released into the cell medium upon damage of the plasma membrane. MCE Cytotoxicity LDH Assay Kit can detect LDH activity in the culture supernatant, which is indicative of cytotoxicity.
| Library | Description |
| MCE Anti-Liver Cancer Compound Library |
1,300+ compounds with identified and potential anti-liver cancer activity, which can be used for anti-liver cancer drug screening and related studies. Targeting RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/ B-catenin pathway, insulin-like growth factor pathway, C-met /HGFR pathway and other signaling pathways.
|
| MCE Rare Diseases Drug Library | 1,500+ drugs used in rare diseases treatment, providing corresponding indications for rare diseases. Drug repurposing for new indications is a time-saving and money-saving method with a high success rate, and greatly reduces the risk of drug development for rare diseases. MCE Rare Diseases Drug Library is a useful tool for the research of rare diseases. |
Latest Publications Citing Use of MCE Products
Nature. 2022 Apr;604(7904):160-166.
Nature. 2022 Apr;604(7904):134-140.
Nat Genet. 2022 Apr;54(4):481-491.
Cancer Discov. 2022 Feb;12(2):502-521.
Cell Signaling Pathways
Request Your Quote